MWNA
CERE

Marshall Wace North America’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Marshall Wace North America’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-48,583
Closed -$667K – 1859
2021
Q1 		$667K Sell
48,583
-145,219
-75% -$2.12M ﹤0.01% 1137
2020
Q4 		$3.21M Buy
+193,802
New +$2.52M 0.01% 642

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Marshall Wace North America's CERE Position: Q2 2021 in Review

Marshall Wace North America sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q2 2021, closing a stake of 48,583 shares — an estimated $667K sold.

Marshall Wace North America first reported a position in CERE in Q4 2020 and held it in 2 quarters. The position peaked at $3.21M in Q4 2020. 82 funds tracked by Wall St. Rank hold CERE as of Q2 2021.

  • Marshall Wace North America reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 48,583 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q2 2021, an estimated $667K.
  • Marshall Wace North America first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Marshall Wace North America's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $3.21M in Q4 2020.
  • 82 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.